When interest rates are low, small-cap stocks begin to shine and outpace larger companies in value. These stocks are stocks with a market capitalization between $300 million and $3 billion.

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Along with conducting plenty of research, I rely on my experience to draw out the most important trends and likely winners for the best stocks to buy. I've covered this story for over a decade now ...

The right online broker can help you execute your investment strategy and make trading cheap stocks seamless. Take a look at some of Benzinga’s favorites. You have found stocks to buy now cheap ...

As a writer, Michael has covered everything from stocks to cryptocurrency and ETFs for many of the world's m... See Full Bio Michael AdamsCryptocurrency and Investing Expert Editor Michael Adams ...

These are some of the best-performing stocks in the health care sector over the past month Nathan Reiff has been writing expert articles and news about financial topics such as investing and ...

Should you have international stocks in your portfolio? If you already have exposure to US large-cap stocks, international stocks could be a logical addition thanks to their potential to improve ...

The telecom giant's high yield appears sustainable, which should attract investors as interest rates come down.

Looking ahead to 2024, the company is planning its largest-ever exploration program that could potentially serve as a bullish catalyst for the stock. One of the best-performing gold producers.

CV Pad, the cutting edge launchpad backed by industry giants CV VC, CV Labs, and DuckDAO, has achieved a major milestone with the successful launch of its first three Initial DEX Offerings (IDOs).

The comments from President and COO Daniel Pinto helped push JPMorgan shares 5.2% lower. Earlier in the year, CEO Jamie Dimon suggested to investors that he thinks the bank's stock is overvalued.

The stock has more than doubled in 2024 but is still trading under $5. Investors are growing increasingly optimistic that imetelstat could gain additional approvals. Geron is in phase 3 clinical ...